Current concepts in the diagnosis and management of Parkinson's disease

CMAJ. Canadian Medical Association Journal

Volumn 168, Issue 3, 2003, Pages 293-301

  Guttman, Mark ^a,b,c,d   Kish, Stephen J ^b,c   Furukawa, Yoshiaki ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PRAMIPEXOLE; PROFENAMINE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL;

BRADYKINESIA; COGNITIVE DEFECT; DIARRHEA; DISEASE EXACERBATION; DRUG MECHANISM; DRY EYE; DYSKINESIA; DYSTONIA; ENVIRONMENTAL FACTOR; GLAUCOMA; HALLUCINATION; HEREDITY; HUMAN; HYPOTENSION; LUNG FIBROSIS; MENTAL DISEASE; NAUSEA; PARKINSON DISEASE; PERIPHERAL EDEMA; PSYCHOSIS; RASH; REVIEW; RIGIDITY; SLEEP DISORDER; SOMNOLENCE; TREMOR; URINE RETENTION; VERTIGO; XEROSTOMIA;

EID: 0037418066     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: increased mortality compared to controls in a large cohort study. Neurology 2001 ;57:2278-82.
2. Guttman M, Slaughter PM, Theriault ME, BeBoer DP, Naylor CD. Burden of parkinsonism: a population-based study. Mov Disord. In press.
3. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med 1998;339(15):1044-53.
4. Lang AE, Lozano AM. Parkinson's disease: second of two parts. N Engl J Med 1998;339:1130-43.
5. Rascol O, Goetz C, Koller WC, Poewe WH, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359:1589-98.
6. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-4.
7. Dagher A. Functional imaging in Parkinson's disease. Semin Neurol 2001;21(1):23-32.
8. Brucke T, Djamshidian S, Benesits G, Pirker W, Asenbaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000;247(Suppl 4): IV2-7.
9. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-80.
10. Stoessl AJ. Etiology of Parkinson's disease. Can J Neurol Sci 1999;26(Suppl 2):S5-12.
11. Gasser T. Genetics of Parkinson's disease. J Neurol 2001;248:840.
12. Valente EM, Brancati F, Ferraris A, Graham EA, Davis MB, Breteler MMB, et al. PARK6-linked parkinsonism occurs in several European families. Ann Neurol 2002;51(14):18.
13. Van Duijin CM, Dekker MCJ, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJLM. Park 7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001;69:629-34.
14. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson's disease in twins: an etiology study. JAMA 1999;281:341-6.
15. DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, et al. Genome-wide scan for Parkinson's disease: the GenePD study. Neurology 2001;57:1124-6.
16. Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al. Complete genomic screen in Parkinson's disease. JAMA 2001;286:2239-44.
17. Sveinbjornsdottir S, Hicks AA, Jonsson T, Petursson H, Guomundsson G, Frigge ML et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000;343:1765-70.
18. Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002;52(5):549-55.
19. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson's disease. Neurology 2002;58:179-85.
20. Parkinson Study Group. Effects of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71.
21. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:1036-42.
22. Miyasaki JM, Martin WRW, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence based review. Neurology 2002;58:11-7.
23. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate release and controlled release carbidopa/levodopa in Parkinson's disease: a multicentre 5-year study. Eur Neurol 1997;37:23-7.
24. Rascol O, Brooks DJ, Korczyn A, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91.
25. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA 2000;284:1931-8.
26. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001;57(9):1687-94.
27. Guttman M, International Pramipexole-Bromocriptine Study Group. Double blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997;49:1060-3.
28. Verhagen Metman L, Del Dotto P, van den Munchkhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-6.
29. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorder Group. JAMA 2002;287(4):455-63.
30. Moller H. Antiparkinsonian drugs and "sleep attacks". Can ADR Newsl 2001; 11(2):1-2. [Also available in CMAJ 2001;164(7):1038-9.]
31. Eskandar EN, Cosgrove GR, Shinobu LA. Surgical treatment of Parkinson disease. JAMA 2001;286:3056-9.
32. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-63.